Cargando…
Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was plann...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355976/ https://www.ncbi.nlm.nih.gov/pubmed/25884390 http://dx.doi.org/10.1186/s12958-015-0014-3 |
_version_ | 1782360935205175296 |
---|---|
author | Tartagni, Massimo Cicinelli, Maria V Baldini, Domenico Tartagni, Mario V Alrasheed, Hala DeSalvia, Maria A Loverro, Giuseppe Montagnani, Monica |
author_facet | Tartagni, Massimo Cicinelli, Maria V Baldini, Domenico Tartagni, Mario V Alrasheed, Hala DeSalvia, Maria A Loverro, Giuseppe Montagnani, Monica |
author_sort | Tartagni, Massimo |
collection | PubMed |
description | BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile women with advanced reproductive age and normal ovarian reserve. METHODS: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36–40 years old were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment, patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo. The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred embryos and score of leading embryos transferred. RESULTS: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P < 0.05). Conversely, miscarriage rate was higher for patients in the control group (P < 0.05). CONCLUSIONS: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced reproductive age and normal ovarian reserve. |
format | Online Article Text |
id | pubmed-4355976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43559762015-03-12 Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old Tartagni, Massimo Cicinelli, Maria V Baldini, Domenico Tartagni, Mario V Alrasheed, Hala DeSalvia, Maria A Loverro, Giuseppe Montagnani, Monica Reprod Biol Endocrinol Research BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile women with advanced reproductive age and normal ovarian reserve. METHODS: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36–40 years old were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment, patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo. The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred embryos and score of leading embryos transferred. RESULTS: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P < 0.05). Conversely, miscarriage rate was higher for patients in the control group (P < 0.05). CONCLUSIONS: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced reproductive age and normal ovarian reserve. BioMed Central 2015-03-09 /pmc/articles/PMC4355976/ /pubmed/25884390 http://dx.doi.org/10.1186/s12958-015-0014-3 Text en © Tartagni et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tartagni, Massimo Cicinelli, Maria V Baldini, Domenico Tartagni, Mario V Alrasheed, Hala DeSalvia, Maria A Loverro, Giuseppe Montagnani, Monica Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title | Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title_full | Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title_fullStr | Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title_full_unstemmed | Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title_short | Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
title_sort | dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355976/ https://www.ncbi.nlm.nih.gov/pubmed/25884390 http://dx.doi.org/10.1186/s12958-015-0014-3 |
work_keys_str_mv | AT tartagnimassimo dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT cicinellimariav dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT baldinidomenico dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT tartagnimariov dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT alrasheedhala dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT desalviamariaa dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT loverrogiuseppe dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold AT montagnanimonica dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold |